Steven Cohen C4 Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 196,466 shares of CCCC stock, worth $583,504. This represents 0.0% of its overall portfolio holdings.
Number of Shares
196,466
Previous 1,201,848
83.65%
Holding current value
$583,504
Previous $6.85 Million
89.68%
% of portfolio
0.0%
Previous 0.02%
Shares
13 transactions
Others Institutions Holding CCCC
# of Institutions
125Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$20.7 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$20.4 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$18 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$14.5 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$13.5 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $145M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...